Question explored with the scientific record
Conversation so far
- 1 Cold peptides
- 2 peptides for common colds or flu
Answered on this page ↓
peptides for common colds or flu
No peptide has been shown to prevent or treat a common cold or flu in people. The flu peptide work is all cells and mice.
The most developed flu peptide is 12B, an engineered amyloid that binds the influenza A PB2 protein. In cells it cut viral plaques by about 80% at 10 µM, with an IC50 near 1.79 µM [1]. In mice given 2.5 mg/kg intravenously for six days, it produced only a small reduction in lung virus versus buffer and Tamiflu [1]. It does nothing against influenza B [1]. That is a long way from a cold remedy.
| Peptide | Model | Result | Human data |
|---|---|---|---|
| 12B (anti-PB2) | Cells, mice [1] | ~80% plaque cut; small mouse titer drop [1] | None |
| P10/P24 (mRNA-encoded) | Cells only [5] | ~1000-fold titer cut in A549 [5] | None |
| FluPep / super FluPep | Cells only [3] | IC50 down to 0.09 nM [3] | None |
| Cyclic peptides vs HA | Cells only [2] | Binding ~10-15 nM [2] | None |
| 3L11 antibody | Mice [4] | 100% survival at 30 mg/kg [4] | None |
For colds, the peptide-adjacent work is a rhinovirus 3C protease structure used to design inhibitors [7], and a soluble ICAM-1 decoy (Tremacamra) that cut symptoms about 45% and colds about 23% in experimental infection [6]. Tremacamra is a protein, not a peptide you can buy, and it was tested in volunteers deliberately infected, not in natural colds.
Nothing here is a product. The cell and mouse numbers are mechanism, not proof for a person. No trial in this set gave a peptide to people with a cold or flu and measured whether they got better.
My call: skip peptide cold and flu products; the human evidence does not exist. Confidence: moderate.
Sources used 7
-
Reverse engineering synthetic antiviral amyloids
Engineered APR-based synthetic amyloids selectively bind viral proteins to trigger targeted aggregation, inhibiting influenza A PB2–dependent replication in cells and in vivo, with APR-specific activity that extends to ZIKV and shows no effect on influenza B.
DOI: 10.1038/s41467-020-16721-8 -
An ultrasound bioprobe for biological imaging
Kadam et al. developed small cyclic peptides that mimic broadly neutralizing antibodies to hemagglutinin, effectively blocking influenza virus entry into cells and demonstrating potential as a new class of antiviral drugs.
DOI: 10.1126/science.358.6362.493-m -
The potent anti-influenza virus activity of FluPep is mediated by interactions with cellular anionic polysaccharides
FluPep's anti-influenza virus activity is mediated by binding to cellular heparan sulfate and sialic-acid glycans, not to virus particles; replacing its RRKK tract with growth-factor heparin-binding sequences increases potency.
DOI: 10.64898/2026.09.15.751766 -
Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient
3L11 neutralizes H7N9 in vitro and fully protects mice in vivo; epitope near the 150-loop; escape mutations G151R/S152P disrupt binding; Fc-mediated ADCC likely contributes to in vivo protection.
DOI: 10.1016/j.antiviral.2019.104564 -
Affinity-enhanced peptides delivered by mRNA–LNPs inhibit influenza A virus replication by disrupting the PA-PB1 interaction
mRNA-LNP-encoded affinity-enhanced PB1-derived peptides P10 and P24 inhibit influenza A virus replication in cultured cells by disrupting the PA-PB1 polymerase interaction.
DOI: 10.64898/2026.07.29.740963 -
Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection
This study evaluates the efficacy of Tremacamra, a soluble intercellular adhesion molecule 1, in reducing symptoms and viral load in experimental rhinovirus infections through four randomized clinical trials.
DOI: 10.1001/jama.281.19.1797 -
NMR Solution Structures of the Apo and Peptide-Inhibited Human Rhinovirus 3C Protease (Serotype 14): Structural and Dynamic Comparison
This study presents the NMR solution structures of the apo and peptide-inhibited forms of the human rhinovirus 3C protease (HRV14), revealing significant structural and dynamic differences that inform the design of effective protease inhibitors.
DOI: 10.1021/bi7010866